These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23704919)

  • 1. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
    Gao L; Schwartzman J; Gibbs A; Lisac R; Kleinschmidt R; Wilmot B; Bottomly D; Coleman I; Nelson P; McWeeney S; Alumkal J
    PLoS One; 2013; 8(5):e63563. PubMed ID: 23704919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
    Coleman DJ; Gao L; Schwartzman J; Korkola JE; Sampson D; Derrick DS; Urrutia J; Balter A; Burchard J; King CJ; Chiotti KE; Heiser LM; Alumkal JJ
    Sci Rep; 2019 Mar; 9(1):3823. PubMed ID: 30846826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
    Pornour M; Jeon HY; Ryu H; Khadka S; Xu R; Chen H; Hussain A; Lam HM; Zhuang Z; Oo HZ; Gleave M; Dong X; Wang Q; Barbieri C; Qi J
    Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2403331121. PubMed ID: 39052835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer.
    Coleman DJ; Gao L; King CJ; Schwartzman J; Urrutia J; Sehrawat A; Tayou J; Balter A; Burchard J; Chiotti KE; Derrick DS; Sun D; Xia Z; Heiser LM; Alumkal JJ
    Oncogene; 2019 Jul; 38(28):5658-5669. PubMed ID: 30996246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
    Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.
    Bluemn EG; Spencer ES; Mecham B; Gordon RR; Coleman I; Lewinshtein D; Mostaghel E; Zhang X; Annis J; Grandori C; Porter C; Nelson PS
    Mol Cancer Res; 2013 Jun; 11(6):568-78. PubMed ID: 23493267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
    Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
    Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
    Asangani IA; Dommeti VL; Wang X; Malik R; Cieslik M; Yang R; Escara-Wilke J; Wilder-Romans K; Dhanireddy S; Engelke C; Iyer MK; Jing X; Wu YM; Cao X; Qin ZS; Wang S; Feng FY; Chinnaiyan AM
    Nature; 2014 Jun; 510(7504):278-82. PubMed ID: 24759320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
    Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
    PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
    Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
    J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Shah K; Gagliano T; Garland L; O'Hanlon T; Bortolotti D; Gentili V; Rizzo R; Giamas G; Dean M
    Oncogene; 2020 Sep; 39(39):6172-6189. PubMed ID: 32820253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC
    J Biomed Sci; 2011 Aug; 18(1):63. PubMed ID: 21859492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
    Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
    Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
    Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.